Stockpolly
Search
QTTB · NASDAQ · Biotechnology

Q32 Bio (QTTB)

Advances bempikibart, an anti-IL-7Rα antibody, for alopecia areata.

$13.80
Pre-market+0.25 (+1.85%)
At close$13.55(−5.64%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue2−1500000005400
Cost of revenue000000000000
Gross profit2−1500000005400
1011151819151298889
Research & development7810131411754334
235544544555
General & administrative035544544555
Other expenses000000000000
Operating income−8−26−15−18−19−15−12−9−846−8−9
−6−1161101001200
Interest income100010111000
Interest expense000000000001
Other non-operating income6000−2−21000−1200
Income before tax−14−271−17−18−14−11−9−758−8−9
Income tax expense000000000000
Net income from continuing operations−14−271−17−18−14−11−9−758−8−9
Net income−14−271−17−18−14−11−9−758−8−9
EPS, basic−$10.25−$2.27$0.09−$1.42−$1.46−$2.80−$0.90−$0.78−$0.60$4.37−$0.54−$0.44
EPS, diluted−$10.25−$2.27$0.09−$1.42−$1.46−$2.76−$0.90−$0.78−$0.60$4.37−$0.54−$0.44
Weighted average shares, basic31212121211121212131414
Weighted average shares, diluted31212121211121212131414
EBITDA−13−26−15−18−177−12−9−758−8−9
Depreciation & amortization000000000000
EBIT−13−26−15−18−177−12−9−758−8−9